22
Participants
Start Date
August 26, 2011
Primary Completion Date
November 16, 2012
Study Completion Date
November 16, 2012
Recombinant antihemophilic factor, plasma/albumin-free method (rAHF-PFM)
Intravenous infusion at a dose of 25 ± 5 IU/kg once per week. After 20 exposure days, the weekly infusions should be continued for as long as possible following the early prophylaxis period. If required by the clinical situation, dosing may be increased to twice weekly or even three times weekly after 20 exposure days, while keeping the low dose.
Indianapolis
New Brunswick
Vienna
Sofia
Kingston
Brno
Bonn
Bremen
Giessen
Munich
Vilnius
Nijmegen
Lublin
Olsztyn
Chelyabinsk
Krasnodar
Saint Petersburg
Belgrade
A Coruña
Collaborators (1)
Baxter Innovations GmbH
INDUSTRY
Baxalta now part of Shire
INDUSTRY